Regulation of the proteasome: Evaluating the lung proteasome as a new therapeutic target

Antioxidants and Redox Signaling

Volumn 21, Issue 17, 2014, Pages 2364-2382

  Meiners, Silke ^a   Keller, Ilona Elisabeth ^a   Semren, Nora ^a   Caniard, Anne ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA 26S; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; PROTEASOME 20S; UNCLASSIFIED DRUG;

ASTHMA; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL PROLIFERATION; CELL TYPE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; GENETIC VARIABILITY; HALF LIFE TIME; HUMAN; IMMUNE RESPONSE; LUNG CANCER; LUNG DISEASE; LUNG FIBROSIS; PATHOGENESIS; PROTEIN ACETYLATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN QUATERNARY STRUCTURE; PROTEIN SUBUNIT; PROTEIN TARGETING; PULMONARY HYPERTENSION; REVIEW; TRANSCRIPTION REGULATION; ANIMAL; ENZYME ACTIVATION; ENZYMOLOGY; LUNG; LUNG DISEASES; METABOLISM;

ANIMALS; CATALYTIC DOMAIN; ENZYME ACTIVATION; HUMANS; LUNG; LUNG DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84907543398     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5798     Document Type: Review

References (205)

1. Agarwal AK, Xing C, DeMartino GN, Mizrachi D, Hernandez MD, Sousa AB, Martnez de Villarreal L, dos Santos HG, and Garg A. PSMB8 encoding the b5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet 87: 866-872, 2010.
2. Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T, Mizushima T, Ichinose K, Nakamura H, Tsujino A, Kawakami A, Matsunaka M, Kasagi S, Kawano S, Kumagai S, Ohmura K, Mimori T, Hirano M, Ueno S, Tanaka K, Tanaka M, Toyoshima I, Sugino H, Yamakawa A, Tanaka K, Niikawa N, Furukawa F,Murata S, Eguchi K, Ida H, and Yoshiura K-I. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci USA 108: 14914-14919, 2011.
3. Bader M, Benjamin S, Wapinski OL, Smith DM, Goldberg AL, and Steller H. A conserved F box regulatory complex controls proteasome activity in Drosophila. Cell 145: 371-382, 2011.
4. Basler M, Dajee M, Moll C, Groettrup M, and Kirk CJ. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 185: 634-641, 2010.
5. Basler M, Kirk CJ, and Groettrup M. The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol 25: 74-80, 2013.
6. Basler M, Lauer C, Moebius J, Weber R, Przybylski M, Kisselev AF, Tsu C, and Groettrup M. Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation. J Immunol 189: 1868-1877, 2012.
7. Basler M, Moebius J, Elenich L, Groettrup M, and Monaco JJ. An altered T cell repertoire in MECL-1-deficient mice. J Immunol 176: 6665-6672, 2006.
8. Belcher CN and Vij N. Protein processing and inflammatory signaling in cystic fibrosis: challenges and therapeutic strategies. Curr Mol Med 10: 82-94, 2010.
9. Benko S, Magalhaes JG, Philpott DJ, and Girardin SE. NLRC5 limits the activation of inflammatory pathways. J Immunol 185: 1681-1691, 2010.
10. Besche HC, Peth A, and Goldberg AL. Getting to first base in proteasome assembly. Cell 138: 25-28, 2009.
11. Bingol B, Wang C-F, Arnott D, Cheng D, Peng J, and Sheng M. Autophosphorylated CaMKIIalpha acts as a scaffold to recruit proteasomes to dendritic spines. Cell 140: 567-578, 2010.
12. Biswas A, Meissner TB, Kawai T, and Kobayashi KS. Cutting edge: impaired MHC class I expression in mice deficient for Nlrc5/class I transactivator. J Immunol 189: 516-520, 2012.
13. Blickwedehl J, Agarwal M, Seong C, Pandita RK, Melendy T, Sung P, Pandita TK, and Bangia N. Role for proteasome activator PA200 and postglutamyl proteasome activity in genomic stability. Proc Natl Acad Sci USA 105: 16165-16170, 2008.
14. Blickwedehl J, McEvoy S, Wong I, Kousis P, Clements J, Elliott R, Cresswell P, Liang P, and Bangia N. Proteasomes and proteasome activator 200 kDa (PA200) accumulate on chromatin in response to ionizing radiation. Radiat Res 167: 663-674, 2007.
15. Bose S, Stratford FLL, Broadfoot KI, Mason GGF, and Rivett AJ. Phosphorylation of 20S proteasome alpha subunit C8 (alpha7) stabilizes the 26S proteasome and plays a role in the regulation of proteasome complexes by gamma-interferon. Biochem J 378: 177-184, 2004.
16. Bouchecareilh M and Balch WE. Proteostasis: a new therapeutic paradigm for pulmonary disease. Proc Am Thorac Soc 8: 189-195, 2011.
17. Breusing N and Grune T. Regulation of proteasomemediated protein degradation during oxidative stress and aging. Biol Chem 389: 203-209, 2008.
18. Bulteau AL, Verbeke P, Petropoulos I, Chaffotte AF, and Friguet B. Proteasome inhibition in glyoxal-treated fibroblasts and resistance of glycated glucose-6-phosphate dehydrogenase to 20 S proteasome degradation in vitro. J Biol Chem 276: 45662-45668, 2001.
19. Carrard G, Dieu M, Raes M, Toussaint O, and Friguet B. Impact of ageing on proteasome structure and function in human lymphocytes. Int J Biochem Cell Biol 35: 728-739, 2003.
20. Chu-Ping M, Slaughter CA, and DeMartino GN. Purification and characterization of a protein inhibitor of the 20S proteasome (macropain). Biochim Biophys Acta 1119: 303-311, 1992.
21. Crawford LJ, Walker B, and Irvine AE. Proteasome inhibitors in cancer therapy. J Cell Commun Signal 5: 101-110, 2011.
22. Cui J, Zhu L, Xia X, Wang HY, Legras X, Hong J, Ji J, Shen P, Zheng S, Chen ZJ, and Wang R-F. NLRC5 Negatively regulates the NF-jB and type I interferon signaling pathways. Cell 141: 483-496, 2010.
23. Dahlmann B. Proteasomes. Essays Biochem 41: 38-48, 2005.
24. Dahlmann B, Ruppert T, Kuehn L, Merforth S, and Kloetzel PM. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol 303: 643-653, 2000.
25. Day SM, Divald A, Wang P, Davis F, Bartolone S, Jones R, and Powell SR. Impaired assembly and post-translational regulation of 26S proteasome in human end-stage heart failure. Circ Heart Fail 6: 544-549, 2013.
26. de Verteuil D, Muratore-Schroeder TL, Granados DP, Fortier M-H, Hardy M-P, Bramoullé A, Caron E, Vincent K, Mader S, Lemieux S, Thibault P, and Perreault C. Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol Cell Proteomics 9: 2034-2047, 2010.
27. Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L, Hong C, Hittinger L, Ghaleh B, Sadoshima J, Vatner DE, Vatner SF, and Madura K. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114: 1821-1828, 2006.
28. Dick LR and Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 15: 243-249, 2010.
29. Ding Q, Martin S, Dimayuga E, Bruce-Keller AJ, and Keller JN. LMP2 knock-out mice have reduced proteasome activities and increased levels of oxidatively damaged proteins. Antioxid Redox Signal 8: 130-135, 2006.
30. Djakovic SN, Marquez-Lona EM, Jakawich SK, Wright R, Chu C, Sutton MA, and Patrick GN. Phosphorylation of Rpt6 regulates synaptic strength in hippocampal neurons. J Neurosci 32: 5126-5131, 2012.
31. Djakovic SN, Schwarz LA, Barylko B, DeMartino GN, and Patrick GN. Regulation of the proteasome by neuronal activity and calcium/calmodulin-dependent protein kinase II. J Biol Chem 284: 26655-26665, 2009.
32. Drews O, Tsukamoto O, Liem D, Streicher J, Wang Y, and Ping P. Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. Circ Res 107: 1094-1101, 2010.
33. Ebstein F, Kloetzel P-M, Krüger E, and Seifert U. Emerging roles of immunoproteasomes beyond MHC class I antigen processing. Cell Mol Life Sci 69: 2543-2558, 2012.
34. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, and Johnston SL. Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 121: 1-13, 2009.
35. El-Hashim AZ, Renno WM, Abduo HT, Jaffal SM, Akhtar S, and Benter IF. Effect of inhibition of the ubiquitin-proteasome-system and IjB kinase on airway inflammation and hyperresponsiveness in a murine model of asthma. Int J Immunopathol Pharmacol 24: 33-42, 2011.
36. Eleftheriadis T. The existence of two types of proteasome, the constitutive proteasome and the immunoproteasome, may serve as another layer of protection against autoimmunity. Med Hypotheses 78: 138-141, 2012.
37. Elliott PJ, Pien CS,McCormack TA,Chapman ID, and Adams J. Proteasome inhibition: a novel mechanism to combat asthma. J Allergy Clin Immunol 104: 294-300, 1999.
38. Elliott PJ, Zollner TM, and Boehncke W-H. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med (Berl) 81: 235-245, 2003.
39. Escobar M, Velez M, Belalcazar A, Santos ES, and Raez LE. The role of proteasome inhibition in nonsmall cell lung cancer. J Biomed Biotechnol 2011: 806506, 2011.
40. Farout L and Friguet B. Proteasome function in aging and oxidative stress: implications in protein maintenance failure. Antioxid Redox Signal 8: 205-216, 2006.
41. Fehling H, Swat W, Laplace C, Kuhn R, Rajewsky K, Muller U, and von Boehmer H. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 265: 1234-1237, 1994.
42. Feng Y, Longo DL, and Ferris DK. Polo-like kinase interacts with proteasomes and regulates their activity. Cell Growth Differ 12: 29-37, 2001.
43. Fernandez IE and Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 380: 680-688, 2012.
44. Fineschi S, Bongiovanni M, Donati Y, Djaafar S, Naso F, Goffin L, Argiroffo CB, Pache J-C, Dayer J-M, Ferrari-Lacraz S, and Chizzolini C. In vivo investigations on antifibrotic potential of proteasome inhibition in lung and skin fibrosis. Am J Respir Cell Mol Biol 39: 458-465, 2008.
45. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 78: 477-513, 2009.
46. Funakoshi M, Tomko RJ, Kobayashi H, and Hochstrasser M. Multiple assembly chaperones govern biogenesis of the proteasome regulatory particle base. Cell 137: 887-899, 2009.
47. Garg A, Hernandez MD, Sousa AB, Subramanyam L, Martnez de Villarreal L, dos Santos HG, and Barboza O. An autosomal recessive syndrome of joint contractures, muscular atrophy, microcytic anemia, and panniculitisassociated lipodystrophy. J Clin Endocrinol Metab 95: E58-E63, 2010.
48. Grimberg KB, Beskow A, Lundin D, Davis MM, and Young P. Basic leucine zipper protein Cnc-C is a substrate and transcriptional regulator of the Drosophila 26S proteasome. Mol Cell Biol 31: 897-909, 2011.
49. Grimm S, Höhn A, and Grune T. Oxidative protein damage and the proteasome. Amino Acids 42: 23-38, 2012.
50. Groettrup M, Khan S, Schwarz K, and Schmidtke G. Interferon-gamma inducible exchanges of 20S proteasome active site subunits: why Biochimie 83: 367-372, 2001.
51. Groettrup M, Kirk CJ, and Basler M. Proteasomes in immune cells: more than peptide producers Nat Rev Immunol 10: 73-78, 2010.
52. Groettrup M, Standera S, Stohwasser R, and Kloetzel PM. The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc Natl Acad Sci USA 94: 8970-8975, 1997.
53. Groll M, Bajorek M, Köhler A, Moroder L, Rubin DM, Huber R, Glickman MH, and Finley D. A gated channel into the proteasome core particle. Nat Struct Biol 7: 1062-1067, 2000.
54. Groll MDL, Löwe J, Stock D, Bochtler M, Bartunik HD, and Huber R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386: 463-471, 1997.
55. Grune T. The Proteasomal System in Aging and Disease. Amsterdam, Boston: Elsesvier/Academic Press, 2012.
56. Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, Parvizi G, Bousquet-Dubouch M-P, Theáte I, Parmentier N, and Van den Eynde BJ. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci USA 107: 18599-18604, 2010.
57. Guillaume B, Stroobant V, Bousquet-Dubouch M-P, Colau D, Chapiro J, Parmentier N, Dalet A, and Van den Eynde BJ. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J Immunol 189: 3538-3547, 2012.
58. Guo X, Engel JL, Xiao J, Tagliabracci VS, Wang X, Huang L, and Dixon JE. UBLCP1 is a 26S proteasome phosphatase that regulates nuclear proteasome activity. Proc Natl Acad Sci USA 108: 18649-18654, 2011.
59. Heink S. IFN-g-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci USA 102: 9241-9246, 2005.
60. Heink S. Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency. Cancer Res 66: 649-652, 2006.
61. Hensley SE, Zanker D, Dolan BP, David A, Hickman HD, Embry AC, Skon CN, Grebe KM, Griffin TA, Chen W, Bennink JR, and Yewdell JW. Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses. J Immunol 184: 4115-4122, 2010.
62. Hernebring M, Fredriksson A, Liljevald M, Cvijovic M, Norrman K, Wiseman J, SembH, and NyströmT.Removal of damaged proteins during ES cell fate specification requires the proteasome activator PA28. Sci Rep 3: 1381, 2013.
63. Hoffman L, Pratt G, and Rechsteiner M. Multiple forms of the 20 S multicatalytic and the 26 S ubiquitin/ATPdependent proteases from rabbit reticulocyte lysate. J Biol Chem 267: 22362-22368, 1992.
64. Hogg JC and Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 4: 435-459, 2009.
65. Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk CJ, Groettrup M, and Groll M. Immuno-and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148: 727-738, 2012.
66. Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, and Anolik JH. Novel proteasome inhibitors have a beneficial effect in murine lupus via the dual inhibition of type i interferon and autoantibody secreting cells. Arthritis Rheum 64: 493-503, 2012.
67. Isasa M, Katz EJ, Kim W, Yugo V, González S, Kirkpatrick DS, Thomson TM, Finley D, Gygi SP, and Crosas B. Monoubiquitination of RPN10 regulates substrate recruitment to the proteasome. Mol Cell 38: 733-745, 2010.
68. Joeris T, Schmidt N, Ermert D, Krienke P, Visekruna A, Kuckelkorn U, Kaufmann SHE, and Steinhoff U. The Proteasome system in infection: impact of b5 and LMP7 on composition, maturation and quantity of active proteasome complexes. PLoS One 7: e39827, 2012.
69. Kalim KW, Basler M, Kirk CJ, and Groettrup M. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol 189: 4182-4193, 2012.
70. Kaneko T, Hamazaki J, Iemura S-I, Sasaki K, Furuyama K, Natsume T, Tanaka K, and Murata S. Assembly pathway of the mammalian proteasome base subcomplex is mediated by multiple specific chaperones. Cell 137: 914-925, 2009.
71. Keller JN, Gee J, and Ding Q. The proteasome in brain aging. Ageing Res Rev 1: 279-293, 2002.
72. Kensler TW, Wakabayashi N, and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116, 2007.
73. Khor B, Bredemeyer AL, Huang C-Y, Turnbull IR, Evans R, Maggi LBJ, White JM, Walker LM, Carnes K, Hess RA, and Sleckman BP. Proteasome activator PA200 is required for normal spermatogenesis. Mol Cell Biol 26: 2999-3007, 2006.
74. Kikuchi J, Iwafune Y, Akiyama T, Okayama A, Nakamura H, Arakawa N, Kimura Y, and Hirano H. Co-and post-translational modifications of the 26S proteasome in yeast. Proteomics 10: 2769-2779, 2010.
75. Kim H-J, Ji B-R, Kim J-S, Lee H-N, Ha D-H, and Kim CW. Proteomic analysis of proteins associated with cellular senescence by calorie restriction in mesenchymal stem cells. In Vitro Cell Dev Biol Anim 48: 186-195, 2012.
76. Kim SY, Lee JH, Huh JW, Kim HJ, Park MK, Ro JY, Oh YM, Lee SD, and Lee YS. Bortezomib alleviates experimental pulmonary arterial hypertension. Am J Respir Cell Mol Biol 47: 698-708, 2012.
77. Kincaid EZ, Che JW, York I, Escobar H, Reyes-Vargas E, Delgado JC, Welsh RM, KarowML, Murphy AJ, Valenzuela DM, Yancopoulos GD, and Rock KL. Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol 13: 129-135, 2011.
78. Kingsbury DJ, Griffin TA, and Colbert RA. Novel propeptide function in 20 S proteasome assembly influences beta subunit composition. J Biol Chem 275: 24156-24162, 2000.
79. Kipen HM, Gandhi S, Rich DQ, Ohman-Strickland P, Laumbach R, Fan Z-H, Chen L, Laskin DL, Zhang J, and Madura K. Acute decreases in proteasome pathway activity after inhalation of fresh diesel exhaust or secondary organic aerosol. Environ Health Perspect 119: 658-663, 2011.
80. Kirk R, Laman H, Knowles PP, Murray-Rust J, Lomonosov M, Meziane EK, and McDonald NQ. Structure of a conserved dimerization domain within the F-box protein Fbxo7 and the PI31 proteasome inhibitor. J Biol Chem 283: 22325-22335, 2008.
81. Kish-Trier E and Hill CP. Structural Biology of the Proteasome. Annu Rev Biophys 42: 1-21, 2013.
82. Kitamura A, Maekawa Y, Uehara H, Izumi K, Kawachi I, Nishizawa M, Toyoshima Y, Takahashi H, Standley DM, Tanaka K, Hamazaki J, Murata S, Obara K, Toyoshima I, and Yasutomo K. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Investig 121: 4150-4160, 2011.
83. Koch A, Steffen J, and Krüger E. TCF11 at the crossroads of oxidative stress and the ubiquitin proteasome system. Cell Cycle 10: 1200-1207, 2011.
84. Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, Koch M, Lang G, Fink L, Bohle R-M, Seeger W, Weaver TE, and Guenther A. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 178: 838-846, 2008.
85. Korfei M, von der Beck D, Henneke I, Markart P, Ruppert C, Mahavadi P, Ghanim B, Klepetko W, Fink L, Meiners S, Krämer OH, Seeger W, Vancheri C, and Guenther A. Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP) and organ donors. J Proteomics 85: 109-128, 2013.
86. Kuenzel S, Till A, Winkler M, Häsler R, Lipinski S, Jung S, Grötzinger J, Fickenscher H, Schreiber S, and Rosenstiel P. The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses. J Immunol 184: 1990-2000, 2010.
87. Kunjappu MJ and Hochstrasser M. Assembly of the 20S proteasome. Biochim Biophys Acta 1843: 2-12, 2014.
88. Lara PN Jr., Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ, and Gandara DR. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 1: 996-1001, 2006.
89. Lara PNJ, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DHM, Koczywas M, Wright JJ, Shepherd FA, Leighl N, and Gandara DR. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced nonsmall-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer 12: 33-37, 2011.
90. Lawson WE, Crossno PF, Polosukhin VV, Roldan J, Cheng D-S, Lane KB, Blackwell TR, Xu C, Markin C, Ware LB, Miller GG, Loyd JE, and Blackwell TS. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol 294: L1119-L1126, 2008.
91. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, and Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18: 39-51, 2004.
92. Lei B, Abdul Hameed MDM, Hamza A, Wehenkel M, Muzyka JL, Yao X-J, Kim K-B, and Zhan C-G. Molecular basis of the selectivity of the immunoproteasome catalytic subunit LMP2-specific inhibitor revealed by molecular modeling and dynamics simulations. J Phys Chem B 114: 12333-12339, 2010.
93. Li J, Powell SR and Wang X. Enhancement of proteasome function by PA28a overexpression protects against oxidative stress. FASEB J 25: 883-893, 2011.
94. Li M, Dong X, Liu Y, Sun X, Li Z, and He J. Inhibition of ubiquitin proteasome function suppresses proliferation of pulmonary artery smooth muscle cells. Naunyn Schmiedebergs Arch Pharmacol 384: 517-523, 2011.
95. Li X, Amazit L, Long W, Lonard DM, Monaco JJ, and O'Malley BW. Ubiquitin-and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol Cell 26: 831-842, 2007.
96. Li X, Lonard DM, Jung SY, Malovannaya A, Feng Q, Qin J, Tsai SY, Tsai M-J, and O'Malley BW. The SRC-3/AIB1 coactivator is degraded in a ubiquitin-and ATPindependent manner by the REGgamma proteasome. Cell 124: 381-392, 2006.
97. Lin J-T, Chang W-C, Chen H-M, Lai H-L, Chen C-Y, Tao M-H, and Chern Y. Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease. Mol Cell Biol 33: 1073-1084, 2013.
98. Liu C-W and Jacobson AD. Functions of the 19S complex in proteasomal degradation. Trends Biochem Sci 38: 103-110, 2013.
99. Liu K, Paterson AJ, Zhang F, McAndrew J, Fukuchi K-I, Wyss JM, Peng L, Hu Y, and Kudlow JE. Accumulation of protein O-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high O-GlcNAc metabolism. J Neurochem 89: 1044-1055, 2004.
100. Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, Kim PW, Sheikh A, Lee C-C, Chen Y, Vera A, Zhang X, Goldbach-Mansky R, and Zlotogorski A. Mutations in PSMB8 cause CANDLE syndrome with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 64: 895-907, 2012.
101. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, AlMazroa MA, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Abdulhak AB, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FGR, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo J-P, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Memish ZA, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KMV, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh P-H, Yip P, Zabetian A, Zheng Z-J, Lopez AD, and Murray CJ. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095-2128, 2012.
102. Mackay IR, Rosen FS, Busse WW, and Lemanske RF. Asthma. N Engl J Med 344: 350-362, 2001.
103. Majetschak M, Sorell LT, Patricelli T, Seitz DH, and Knoferl MW. Detection and possible role of proteasomes in the bronchoalveolar space of the injured lung. Physiol Res 58: 363-372, 2009.
104. Malhotra D, Thimmulappa R, Vij N, Navas-Acien A, Sussan T, Merali S, Zhang L, Kelsen SG, Myers A, Wise R, Tuder R, and Biswal S. Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. Am J Respir Crit Care Med 180: 1196-1207, 2009.
105. Mao I, Liu J, Li X, and Luo H. REGgamma, a proteasome activator and beyond Cell Mol Life Sci 65: 3971-3980, 2008.
106. McCutchen-Maloney SL, Matsuda K, Shimbara N, Binns DD, Tanaka K, Slaughter CA, and DeMartino GN. cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome. J Biol Chem 275: 18557-18565, 2000.
107. McElvaney NG and Greene CM. Mechanisms of protein misfolding in conformational lung diseases. Curr Mol Med 12: 850-859, 2012.
108. Meiners S,DregerH, FechnerM,Bieler S,RotherW,Günther C, Baumann G, Stangl V, and Stangl K. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 51: 302-308, 2008.
109. Meiners S and Eickelberg O. What shall we do with the damaged proteins in lung disease Ask the proteasome! Eur Respir J 40: 1260-1268, 2012.
110. Meiners S, Heyken D, Weller A, Ludwig A, Stangl K, Kloetzel P-M, and Krüger E. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem 278: 21517-21525, 2003.
111. Meiners S, Hocher B,Weller A, LauleM, Stangl V, Guenther C, Godes M, Mrozikiewicz A, Baumann G, and Stangl K. Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension 44: 471-477, 2004.
112. Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P, Baumann G, Kloetzel P-M, and Stangl K. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 105: 483-489, 2002.
113. Meiners S, Ludwig A, Stangl V, and Stangl K. Proteasome inhibitors: poisons and remedies. Med Res Rev 28: 309-327, 2008.
114. Meissner TB, Li A, Biswas A, Lee K-H, Liu Y-J, Bayir E, Iliopoulos D, van den Elsen PJ, and Kobayashi KS. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci USA 107: 13794-13799, 2010.
115. Min T, Bodas M, Mazur S, and Vij N. Critical role of proteostasis-imbalance in pathogenesis of COPD and severe emphysema. J Mol Med (Berl) 89: 577-593, 2011.
116. Mishto M, Santoro A, Bellavista E, Sessions R, Textoris-Taube K, Dal Piaz F, Carrard G, Forti K, Salvioli S, Friguet B, Kloetzel PM, Rivett AJ, and Franceschi C. A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms. Biol Chem 387: 417-429, 2006.
117. Mitch WE, Medina R, Grieber S, May RC, England BK, Price SR, Bailey JL, and Goldberg AL. Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. J Clin Investig 93: 2127-2133, 1994.
118. Moebius J, van den Broek M, Groettrup M, and Basler M. Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. Eur J Immunol 40: 3439-3449, 2010.
119. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, and Groettrup M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15: 781-787, 2009.
120. Mulugeta S, Nguyen V, Russo SJ, Muniswamy M, and Beers MF. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol 32: 521-530, 2005.
121. Murata S. Growth retardation in mice lacking the proteasome activator PA28gamma. J Biol Chem 274: 38211-38215, 1999.
122. Murata S, Sasaki K, Kishimoto T, Niwa S-I, Hayashi H, Takahama Y, and Tanaka K. Regulation of CD8 + T cell development by thymus-specific proteasomes. Science 316: 1349-1353, 2007.
123. Murata S, Udono H, Tanahashi N, Hamada N, Watanabe K, Adachi K, Yamano T, Yui K, Kobayashi N, Kasahara M, Tanaka K, and Chiba T. Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta. EMBO J 20: 5898-5907, 2001.
124. Murata S, Yashiroda H, and Tanaka K. Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol 10: 104-115, 2009.
125. Mutlu GM, Budinger GRS, Wu M, Lam AP, Zirk A, Rivera S, Urich D, Chiarella SE, Go LHT, Ghosh AK, Selman M, Pardo A, Varga J, Kamp DW, Chandel NS, Sznajder JI, and Jain M. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-b(1) signalling. Thorax 67: 139-146, 2012.
126. Nathan JA, Spinnenhirn V, Schmidtke G, Basler M, Groettrup M, and Goldberg AL. Immuno-and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 152: 1184-1194, 2013.
127. Neefjes J, Jongsma MLM, Paul P, and Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11: 823-836, 2011.
128. Neerincx A, Lautz K, Menning M, Kremmer E, Zigrino P, Hösel M, Büning H, Schwarzenbacher R, and Kufer TA. A role for the human nucleotide-binding domain, leucinerich repeat-containing family member NLRC5 in antiviral responses. J Biol Chem 285: 26223-26232, 2010.
129. Neerincx A, Rodriguez GM, Steimle V, and Kufer TA. NLRC5 controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner. J Immunol 188: 4940-4950, 2012.
130. NicholsWG, Peck Campbell AJ, and BoeckhM. Respiratory viruses other than influenza virus: impact and therapeutic advances. Clin Microbiol Rev 21: 274-290, 2008.
131. Ortega J, Bernard Heymann J, Kajava AV, Ustrell V, Rechsteiner M, and Steven AC. The axial channel of the 20S proteasome opens upon binding of the PA200 activator. J Mol Biol 346: 1221-1227, 2005.
132. Osna Na, Haorah J, Krutik VM, and Donohue TM. Peroxynitrite alters the catalytic activity of rodent liver proteasome in vitro and in vivo. Hepatology 40: 574-582, 2004.
133. Ottenheijm CAC, Heunks LMA, Li Y-P, Jin B, Minnaard R, van Hees HWH, and Dekhuijzen PNR. Activation of the ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease. Am JRespir Crit Care Med 174: 997-1002, 2006.
134. Pagan J, Seto T, Pagano M, and Cittadini A. Role of the ubiquitin proteasome system in the heart. Circ Res 112: 1046-1058, 2013.
135. Palombella VJ, Rando OJ, Goldberg AL, and Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78: 773-785, 1994.
136. Park S, Kim W, Tian G, Gygi SP, and Finley D. Structural defects in the regulatory particle-core particle interface of the proteasome induce a novel proteasome stress response. J Biol Chem 286: 36652-36666, 2011.
137. Park S, Li X, Kim HM, Singh CR, Tian G, Hoyt Ma, Lovell S, Battaile KP, Zolkiewski M, Coffino P, Roelofs J, Cheng Y, and Finley D. Reconfiguration of the proteasome during chaperone-mediated assembly. Nature 497: 512-516, 2013.
138. Pathare GR, Nagy I, Bohn S, Unverdorben P, Hubert A, Körner R, Nickell S, Lasker K, Sali A, Tamura T, Nishioka T, Förster F, Baumeister W, and Bracher A. The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together. Proc Natl Acad Sci USA 109: 149-154, 2012.
139. Patton JS and Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6: 67-74, 2007.
140. Pickering AM and Davies KJA. Differential roles of proteasome and immunoproteasome regulators Pa28ab, Pa28c and Pa200 in the degradation of oxidized proteins. Arch Biochem Biophys 523: 181-190, 2012.
141. Pickering AM, Koop AL, Teoh CY, Ermak G, Grune T, and Davies KJA. The immunoproteasome, the 20S proteasome and the PA28ab proteasome regulator are oxidative-stress-adaptive proteolytic complexes. Biochem J 432: 585-594, 2010.
142. Pratt G and Rechsteiner M. Proteasomes cleave at multiple sites within polyglutamine tracts: activation by PA28gamma(K188E). J Biol Chem 283: 12919-12925, 2008.
143. Psallidas I, Karabela SP, Moschos C, Sherrill TP, Kollintza A, Magkouta S, Theodoropoulou P, Roussos C, Blackwell TS, Kalomenidis I, and Stathopoulos GT. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. Mol Cancer 9: 56, 2010.
144. Qian MX, Pang Y, Liu CH, Haratake K, Du BY, Ji DY, Wang GF, Zhu QQ, Song W, Yu Y, Zhang XX, Huang HT, Miao S, Chen LB, Zhang ZH, Liang YN, Liu S, Cha H, Yang D, Zhai Y, Komatsu T, Tsuruta F, Li H, Cao C, Li W, Li GH, Cheng Y, Chiba T, Wang L, Goldberg AL, Shen Y, and Qiu XB. Acetylation-mediated proteasomal degradation of core histones during DNA repair and spermatogenesis. Cell 153: 1012-1024, 2013.
145. Rabe KF, Beghé B, Luppi F, and Fabbri LM. Update in chronic obstructive pulmonary disease 2006. Am J Respir Crit Care Med 175: 1222-1232, 2007.
146. Rabinovitch M. Pathobiology of pulmonary hypertension. Annu Rev Pathol 2: 369-399, 2007.
147. Radhakrishnan SK, Lee CS, Young P, Beskow A, Chan JY, and Deshaies RJ. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell 38: 17-28, 2010.
148. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Mü ller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, and Schünemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824, 2011.
149. Raissy HH, Kelly HW, Harkins M, and Szefler SJ. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med 187: 798-803, 2013.
150. Realini C. Characterization of recombinant REGalpha, REGbeta, and REGgamma proteasome activators. J Biol Chem 272: 25483-25492, 1997.
151. Rechsteiner M and Hill CP. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 15: 27-33, 2005.
152. Rockwell CE, Monaco JJ, and Qureshi N. A critical role for the inducible proteasomal subunits LMP7 and MECL1 in cytokine production by activated murine splenocytes. Pharmacology 89: 117-126, 2012.
153. Ryter SW, Chen ZH, Kim HP, and Choi AM. Autophagy in chronic obstructive pulmonary disease: homeostatic or pathogenic mechanism Autophagy 5: 235-237, 2009.
154. Saeki Y, Toh E-A, Kudo T, Kawamura H, and Tanaka K. Multiple proteasome-interacting proteins assist the as-sembly of the yeast 19S regulatory particle. Cell 137: 900-913, 2009.
155. Sakao Y, Kawai T, Takeuchi O, Copeland NG, Gilbert DJ, Jenkins NA, Takeda K, and Akira S. Mouse proteasomal ATPases Psmc3 and Psmc4: genomic organization and gene targeting. Genomics 67: 1-7, 2000.
156. Savulescu AF and Glickman MH. Proteasome activator 200: the heat is on. Mol Cell Proteomics 10: R110.006890, 2011.
157. Schmidt M and Finley D. Regulation of proteasome activity in health and disease. Biochim Biophys Acta 1843: 13-25, 2014.
158. Schmidt N, Gonzalez E, Visekruna A, Kühl AA, Loddenkemper C, Mollenkopf H, Kaufmann SHE, Steinhoff U, and Joeris T. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 59: 896-906, 2010.
159. Schwartz AL and Ciechanover A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 49: 73-96, 2009.
160. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schröter F, Prozorovski T, Lange N, Steffen J, Rieger M, Kuckelkorn U, Aktas O, Kloetzel P-M, and Krüger E. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142: 613-624, 2010.
161. Shen J, Song G, An M, Li X, Wu N, Ruan K, Hu J, and Hu R. The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for nonsmall cell lung cancer therapy. Biomaterials 35: 316-326, 2014.
162. Sijts A, Sun Y, Janek K, Kral S, Paschen A, Schadendorf D, and Kloetzel P-M. The role of the proteasome activator PA28 in MHC class I antigen processing. Mol Immunol 39: 165-169, 2002.
163. Sixt SU, Adamzik M, Spyrka D, Saul B, Hakenbeck J, Wohlschlaeger J, Costabel U, Kloss A, Giesebrecht J, Dahlmann B, and Peters J. Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 179: 1098-1106, 2009.
164. Sixt SU, Alami R, Hakenbeck J, Adamzik M, Kloss A, Costabel U, Jungblut PR, Dahlmann B, and Peters J. Distinct proteasome subpopulations in the alveolar space of patients with the acute respiratory distress syndrome. Mediators Inflamm 2012: 204-250, 2012.
165. Sixt SU, Beiderlinden M, Jennissen HP, and Peters J. Extracellular proteasome in the human alveolar space: a new housekeeping enzyme Am J Physiol Lung Cell Mol Physiol 292: L1280-L1288, 2007.
166. Sixt SU and Dahlmann B. Extracellular, circulating proteasomes and ubiquitin-incidence and relevance. Biochim Biophys Acta 1782: 817-823, 2008.
167. Smith DM, Kafri G, Cheng Y, Ng D, Walz T, and Goldberg AL. ATP binding to PAN or the 26S ATPases causes association with the 20S proteasome, gate opening, and translocation of unfolded proteins. Mol Cell 20: 687-698, 2005.
168. Somborac-Bacura A, van der Toorn M, Franciosi L, Slebos D-J, Zanic-Grubisic T, Bischoff R, and van Oosterhout AJ. Cigarette smoke induces ER stress response and proteasomal dysfunction in human alveolar epithelial cells. Exp Physiol 98: 316-325, 2013.
169. Stadtmueller BM and Hill CP. Proteasome activators. Mol Cell 41: 8-19, 2011.
170. Stadtmueller BM, Kish-Trier E, Ferrell K, Petersen CN, Robinson H, Myszka DG, Eckert DM, Formosa T, and Hill CP. Structure of a proteasome Pba1-Pba2 complex: implications for proteasome assembly, activation, and biological function. J Biol Chem 287: 37371-37382, 2012.
171. Steffen J, Seeger M, Koch A, and Krüger E. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol Cell 40: 147-158, 2010.
172. Sun X-M, Butterworth M, Macfarlane M, Dubiel W, Ciechanover A, and Cohen GM. Function during Apoptosis. Mol Cell 14: 81-93, 2004.
173. Tanaka K, Mizushima T, and Saeki Y. The proteasome: molecular machinery and pathophysiological roles. Biol Chem 393: 217-234, 2012.
174. Toes RE, Nussbaum AK, Degermann S, Schirle M, Emmerich NP, Kraft M, Laplace C, Zwinderman A, Dick TP, Müller J, Schönfisch B, Schmid C, Fehling HJ, Stevanovic S, Rammensee HG, and Schild H. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 194: 1-12, 2001.
175. Tomko RJ Jr. and Hochstrasser M. Molecular architecture and assembly of the eukaryotic proteasome. Annu Rev Biochem 82: 415-445, 2013.
176. Turnbull EL, Rosser MF, and Cyr DM. The role of the UPS in cystic fibrosis. BMC Biochem 8 Suppl 1: S11, 2007.
177. Ustrell V, Hoffman L, Pratt G, and Rechsteiner M. PA200, a nuclear proteasome activator involved in DNA repair. EMBO J 21: 3516-3525, 2002.
178. van Hees H, Ottenheijm C, Ennen L, Linkels M, Dekhuijzen R, and Heunks L. Proteasome inhibition improves diaphragm function in an animal model for COPD. Am J Physiol Lung Cell Mol Physiol 301: L110-L116, 2011.
179. Van Kaer L, Ashton-Rickardt PG, Eichelberger M, Gaczynska M, Nagashima K, Rock KL, Goldberg AL, Doherty PC, and Tonegawa S. Altered peptidase and viralspecific T cell response in LMP2 mutant mice. Immunity 1: 533-541, 1994.
180. van Rijt SH, Keller IE, John G, Kohse K, Yildirim AO, Eickelberg O, and Meiners S. Acute cigarette smoke exposure impairs proteasome function in the lung. Am J Physiol Lung Cell Mol Physiol 303: L814-L823, 2012.
181. Vernace VA, Arnaud L, Schmidt-Glenewinkel T, and Figueiredo-Pereira ME. Aging perturbs 26S proteasome assembly in Drosophila melanogaster. FASEB J 21: 2672-2682, 2007.
182. Vij N, Min T, Marasigan R, Belcher CN, Mazur S, Ding H, Yong K-T, and Roy I. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J Nanobiotechnol 8: 22, 2010.
183. Vilchez D, Morantte I, Liu Z, Douglas PM, Merkwirth C, Rodrigues APC, Manning G, and Dillin A. RPN-6 determines C. elegans longevity under proteotoxic stress conditions. Nature 489: 263-268, 2012.
184. Volkov A, Hagner S, Löser S, Alnahas S, Raifer H, Hellhund A, Garn H, and Steinhoff U. b5i subunit deficiency of the immunoproteasome leads to reduced Th2 response in OVA induced acute asthma. PLoS One 8: e60565, 2013.
185. Wang D, Fang C, Zong NC, Liem DA, Cadeiras M, Scruggs SB, Yu H, Kim AK, Yang P, Deng M, Lu H, and Ping P. Regulation of acetylation restores proteolytic function of diseased myocardium in mouse and Human. Mol Cell Proteomics 12: 3793-3802, 2013.
186. Wang W-J. Deletion of exon 4 from human surfactant protein C results in aggresome formation and generation of a dominant negative. J Cell Sci 116: 683-692, 2002.
187. Wang X, Li J, Zheng H, Su H, and Powell SR. Proteasome functional insufficiency in cardiac pathogenesis. Am J Physiol Heart Circ Physiol 301: H2207-H2219, 2011.
188. Wang XH, Zhang L, Mitch WE, LeDoux JM, Hu J, and Du J. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J Biol Chem 285: 21249-21257, 2010.
189. Ware L. Pathophysiology of Acute Lung Injury and the Acute Respiratory Distress Syndrome. Semin Respir Crit Care Med 27: 337-349, 2006.
190. Wegmann M, Lunding L, Orinska Z, Wong DM, Manz RA, and Fehrenbach H. Long-term bortezomib treatment reduces allergen-specific IgE but fails to ameliorate chronic asthma in mice. Int Arch Allergy Immunol 158: 43-53, 2012.
191. Wehenkel M, Ban J-O, Ho Y-K, Carmony KC, Hong JT, and Kim KB. A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer 107: 53-62, 2012.
192. Weissman AM, Shabek N, and Ciechanover A. The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat Rev Mol Cell Biol 12: 605-620, 2011.
193. Wilck N and Ludwig A. Targeting the ubiquitin-proteasome system in atherosclerosis: status quo, challenges and perspectives. Antioxid Redox Signal 21: 2344-2363, 2014.
194. Xie Y and Varshavsky A. RPN4 is a ligand, substrate, and transcriptional regulator of the 26S proteasome: a negative feedback circuit. Proc Natl Acad Sci USA 98: 3056-3061, 2001.
195. Xu J, Wang S, Viollet B, and Zou M-H. Regulation of the proteasome by AMPK in endothelial cells: the role of OGlcNAc transferase (OGT). PLoS one 7: e36717, 2012.
196. Xu J, Wang S, Wu Y, Song P, and Zou M-H. Tyrosine nitration of PA700 activates the 26S proteasome to induce endothelial dysfunction in mice with angiotensin II-induced hypertension. Hypertension 54: 625-632, 2009.
197. Xu J, Wang S, Zhang M, Wang Q, Asfa S, and Zou MH. Tyrosine nitration of PA700 links proteasome activation to endothelial dysfunction in mouse models with cardiovascular risk factors. PLoS One 7: e29649, 2012.
198. Yao Y, Wang Y, Chen F, Huang Y, Zhu S, Leng Q, Wang H, Shi Y, and Qian Y. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens. Cell Res 22: 836-847, 2012.
199. Zaiss DM, Standera S, Holzhütter H, Kloetzel P, and Sijts AJ. The proteasome inhibitor PI31 competes with PA28 for binding to 20S proteasomes. FEBS Lett 457: 333-338, 1999.
200. Zaiss DMW, Bekker CPJ, Gröne A, Lie BA, and Sijts AJAM. Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases. J Immunol 187: 2302-2309, 2011.
201. Zaiss DMW, de Graaf N, and Sijts AJAM. The proteasome immunosubunit multicatalytic endopeptidase complexlike 1 is a T-cell-intrinsic factor influencing homeostatic expansion. Infect Immun 76: 1207-1213, 2008.
202. Zanker D, Waithman J, Yewdell JW, and Chen W. Mixed proteasomes function to increase viral peptide diversity and broaden antiviral CD8 + T cell responses. J Immunol 191, 52-59, 2013.
203. Zhang F, Hu Y, Huang P, Toleman CA, Paterson AJ, and Kudlow JE. Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J Biol Chem 282: 22460-22471, 2007.
204. Zhang F, Paterson AJ, Huang P, Wang K, and Kudlow JE. Metabolic control of proteasome function. Physiology (Bethesda) 22: 373-379, 2007.
205. Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, and Kudlow JE. O-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell 115: 715-725, 2003.